Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pemetrexed disodium (Eli Lilly).

P Norman1

  • 1Norman Consulting, Burnham, Bucks, UK. peter.norman2@btinternet.com

Current Opinion in Investigational Drugs (London, England : 2000)
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Working with Insulin, Carbohydrates, Ketones and Exercise to Manage Diabetes (WICKED): evaluation of a self-management course for young people with Type 1 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2019
Same author

Experiences of self-management among young adults with Type 1 diabetes in the context of a structured education programme: a qualitative study.

Diabetic medicine : a journal of the British Diabetic Association·2018
Same author

Optical absorption and magnetic circular dichroism spectra of thiouracils: a quantum mechanical study in solution.

Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology·2017
Same author

Geographic variation in the treatment of non-ST-segment myocardial infarction in the English National Health Service: a cohort study.

BMJ open·2016
Same author

The importance of mindfulness in psychosocial distress and quality of life in dermatology patients.

The British journal of dermatology·2016
Same author

Patient and hospital determinants of primary percutaneous coronary intervention in England, 2003-2013.

Heart (British Cardiac Society)·2016
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Pemetrexed is a multitargeted antifolate drug showing promise for solid tumors like lung cancer. Clinical trials indicate its efficacy and manageable toxicity, especially when supplemented with folic acid and vitamin B12.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Pemetrexed is an investigational antifolate drug targeting thymidylate synthase (TS) and dihydrofolate reductase (DHFR).
  • It functions as a multitargeted antifolate (MTA), inhibiting multiple folate-dependent enzymes crucial for cancer cell proliferation.

Purpose of the Study:

  • To evaluate the efficacy and safety of pemetrexed as a potential treatment for various solid tumors.
  • To assess pemetrexed's response rates in patients with advanced breast cancer, including those refractory to prior therapies.

Main Methods:

  • Phase I, II, and III clinical trials were conducted to assess pemetrexed's efficacy and toxicity.
  • Studies involved patients with non-small cell lung cancer, mesothelioma, and advanced breast cancer.

Main Results:

Related Experiment Videos

  • Pemetrexed demonstrated encouraging response rates in advanced breast cancer patients, including those with anthracycline-failure or taxane-pretreated disease.
  • Supplementation with folic acid and vitamin B12 was shown to reduce pemetrexed's toxicities.
  • The drug was safely administered to patients with impaired renal function.

Conclusions:

  • Pemetrexed exhibits a multitargeted antifolate mechanism with potential in treating common solid tumors.
  • Its toxicity profile is manageable, particularly with vitamin supplementation, and it can be safely used in patients with renal impairment.